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Attachment of alloc protecting groups to the amidine units of fluorogenic DNA-binding bisbenzamidines or
to the amino groups of ethidium bromide leads to a significant reduction of their DNA affinity. More
importantly, the active DNA-binding species can be readily regenerated by treatment with ruthenium
catalysts in aqueous conditions, even in cell cultures. The catalytic chemical uncaging can be easily
monitored by fluorescence microscopy, because the protected products display both different emission
properties and cell distribution to the parent compounds.Introduction
A major research goal in chemical biology is the efficient and
selective targeting of double stranded DNA with small mole-
cules. Towards this goal, a wide range of synthetic DNA binders,
from small molecules to larger peptides, have been developed
over the years.1 In addition to the search for better sequence
selectivity,2 there is also an increased focus on the external
control of the DNA binding of these molecules, so that they can
be activated when and where required at will.3 In this context,
we have recently described a photo-uncaging strategy for
controlling the non-covalent DNA interaction of DNA-binding
agents, such as those shown in the Fig. 1.4
Although irradiation with light represents a clean and simple
way of activating molecules in a spatiotemporally controlled
way, the potential biological application of the strategy is
limited by the low penetrability of the UV light typically used for
photolysis and the likely secondary damage to the tissues. Other
alternatives for the generation of bioactive agents in an exter-
nally controlled manner are therefore highly desirable. Partic-
ularly appealing is the possibility of releasing the active
molecules by using a catalytic reaction that could be performed,
for instance, by specic enzymes.5 Although the use of naturally
occurring biocatalysts is attractive, its scope is intrinsically
limited to a relatively small number of transformations and to
compounds that could be recognized as substrates by the
enzymes. A promising alternative to enzymes could be the use ofro Singular de Investigación en Qúımica
QUS), Universidade de Santiago de
la, Spain. E-mail: joseluis.mascarenas@
n (ESI) available: Synthesis and
s and required precursors. NMR, UV,
control experiments, and detailed
o-staining experiments. See DOI:
hemistry 2014transition metal catalysts. Curiously, despite the extensive use
of organometallic catalysis in synthetic chemistry, metal-based
catalytic reactions have largely been overlooked in biological
settings.6 While applying organometallic catalysis in aqueous
media is not straightforward, several relevant metal-catalyzed
reactions have been successfully used in biocompatible
solvents, and even in cells,7 and it is foreseeable that the next
few years will bring a rapid increase in the use of metal catalysis
in biological environments. Particularly relevant in this area is
the seminal work by E. Meggers and coworkers, who have
demonstrated that ruthenium catalysts, combined with thio-
phenol, can be used to uncage alloc-protected rhodamines in
aqueous media (MeOH/H2O, 95 : 5), and even inside HeLa cells,
without signicantly inuencing the cell viability.8
Owing to our recent demonstration that caging the amidi-
nium groups of bisbenzamidines, or the amino groups of
ethidium, with photolabile nitrobenzyl groups suppresses their
DNA interaction,4 we wondered whether simple alloc-protectingFig. 1 Structure of selected DNA binders: pentamidine (1), prop-
amidine (2), phenyl azapentamidine (3), DAPI (4) ethidium bromide (5).
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Fig. 2 Top: Structures of the alloc (©3), and allyl (6) protected deriv-
atives of bisbenzamidine 3. Bottom: fluorescence emission of 5 mM
solutions of 3 and ©3 in Tris–HCl 20 mM, 100 mM NaCl, pH 7.5
(dashed lines), and in the presence of 1 equiv. of h-A3$T3 (solid lines).
h-A3$T3: 50-GGC-AAATTT-CAGTTTTTCTG-AAATTT-GCC-30.
































































































View Article Onlinegroups might also prevent DNA binding, which would raise
the possibility of using metal-p-allyl chemistry for catalytic
uncaging.
Herein we demonstrate the viability of this temporary allyl-
carbamate protecting approach for controlling the DNA binding
of representative minor groove binders, such as bisbenzami-
dines, (3 and 4, Fig. 1), and of classic intercalators, like
ethidium bromide (5, Fig. 1). Importantly, we also show that the
uncaging reaction can be efficiently performed in living cells
and that the redistribution of the released dyes can be moni-
tored by uorescence microscopy. This work represents the rst
demonstration of the use of metal catalysis to trigger DNA
binding events in live cells.
Results and discussion
Synthesis and in vitro uorescence studies of protected
derivatives of 3
Bisbenzamidines like pentamidine (1) or propamidine (2) are
structurally simple DNA binders that show good stability,
sequence selectivity, and excellent internalization properties in
a variety of cell lines.9 Although rather toxic, pentamidine and
some of its derivatives are being used for the treatment of
Pneumocystis carinii, Leishmaniasis or early-phase African
sleeping sickness, among other diseases.10 Their mode of action
is attributed to their ability to interact with the A/T-rich mito-
chondrial DNA of the parasites.11 We have recently shown that
substitution of the oxygen atom of classic bis-benzamidines by a
nitrogen generates aza derivatives, such as phenyl aza-pent-
amidine 3, with DNA-dependent uorescent properties.12 These
derivatives can be easily synthesized in a single step by reductive
amination of commercial dialdehydes.13 The uorogenic prop-
erties of these molecules resemble those of other DNA binders
that are widely used as uorescent stains, such as the blue
nuclear stain DAPI (40,6-diamidino-2-phenylindole, 4; Fig. 1) or
ethidium bromide (5, Fig. 1).14
Installation of the alloc protecting groups in the aza-pent-
amidine 3 was readily accomplished by reaction with allyl
chloroformate in the presence of NaOH in H2O/THF (85%
yield). The resulting dialloc protected derivative ©3 displays a
relatively weak uorescence intensity and slightly red-shied
emission in comparison to 3. As expected, while incubation of 3
with a hairpin oligonucleotide featuring an A/T-rich site
(h-A3$T3) leads to a large increase in its uorescence emission
upon irradiation at 320 nm, ©3 displays only a very modest
emission intensity enhancement under the same conditions
(Fig. 2).
Titration of ©3 with the oligonucleotide h-A3$T3 allowed us
to calculate an apparent dissociation constant of z21 mM,
which is over 30 times weaker than that exhibited by 3 for this
same oligo (Kd [3] z 0.7 mM).13 The lower DNA affinity of the
alloc-protected ©3 with respect to 3 can be attributed to the loss
of the electrostatic and hydrogen bonding interactions of the
amidinium groups in the caged derivative.15 This hypothesis is
consistent with the results obtained with the analogous bis-
benzamidine bis-allyl derivative 6, which, in contrast to ©3,
displays comparable binding affinity to that of the unprotected1902 | Chem. Sci., 2014, 5, 1901–1907amidinium derivative 3 (Kd [6]z 0.5 mM, see ESI†). As expected,
©3 also shows a very small increase in its emission intensity
upon incubation with a G/C-rich oligonucleotide (see the ESI†).Catalytic uncaging
The deprotection reaction was rst carried out by treatment of
©3 with thiophenol (5 equiv.) and 10% of ruthenium catalyst
RuCp*(COD)Cl ([Ru]), at room temperature (rt) in MeOH/H2O
(95 : 5). High-performance liquid chromatography (HPLC)
analysis of the reaction mixture aer 20 min barely shows any
starting material and the major peak corresponds to the parent
bisbenzamidine 3. Importantly, the reaction can also be effi-
ciently carried out in more biologically relevant media (phos-
phate buffer 100 mM, pH 7.5, and 10% DMSO), although, under
these conditions, aer 20 min we still observe a minor amount
of the mono-protected product m-©3 (Fig. 3). Continuing the
reaction for a longer time did not produce a signicant change
in the proportion of the products (85 : 15).
The deprotection reaction could also be carried out with Pd
catalysts using standard conditions for alloc removal.16 Treat-
ment of ©3 with Pd(OAc)2, N-methyl morpholine, PPh3 and
PhSiH3 in 100 mM phosphate buffer pH 7.5, and 10% DMSO,
thus led to an almost quantitative conversion to 3 aer 5 min; as
expected, this deprotection did not proceed in the absence of
the additives (see the ESI†).
The Ru-catalyzed deprotection also takes place in the pres-
ence of calf thymus DNA (ct-DNA), although in this case aer
20 min at rt we observed the formation of a 15 : 45 : 40 mixture
of the free (3), monoprotected (m-©3) and fully protected
(©3) products, respectively (see the ESI†). Given that the
deprotection reactions generate different amounts of theThis journal is © The Royal Society of Chemistry 2014
Fig. 3 Top: catalytic deprotection in phosphate buffer and 10%
DMSO. Bottom: HPLC trace of the uncaging reaction in phosphate
buffer 100 mM pH 7.5, and 10% DMSO. (a) ©3 (75 mM); (b) ©3 +
PhSH (325 mM); (c)©3 + PhSH + [Ru] (10%), t¼ 1 min; (d)©3 + PhSH +
[Ru], t ¼ 20 min.
Fig. 4 Top: Structure of©4. Bottom: fluorescence spectra of DAPI (4)
and©4 in the absence (dashed lines) and in the presence of 1 equiv. of
h-A2$T2 (solid lines). Experiments were carried out using 0.2 mM of©4
and 4 in TrisHCl 20 mM, 100 mM NaCl, pH 7.5 at 20 C. Sequence of:
h-A2$T2: 50-GGCG AATT CAGCTTTTTGCTG AATT GCC-30.
































































































View Article Onlinemonoprotected derivative m-©3, we studied its DNA binding
properties. Unsurprisingly, titration of m-©3 with h-A3$T3
revealed that this compound binds to the DNA with an inter-
mediate affinity to that of the bis-alloc-protected product ©3
and the parent unprotected molecule 3 (Kd [m-©3] z 6.0 mM,
see the ESI†).Fig. 5 Top: Structure of©5. Bottom: fluorescence emission spectra of
1 mM 5 and ©5 (dashed lines), and spectra of both compounds in the
presence of 0.3 mg mL1 of ct-DNA (solid lines). Spectra of 5 and of 5
in the presence of ct-DNA are represented multiplied by a factor of 10
for comparison. lexc 5 ¼ 545 nm, lexc ©5 ¼ 300 nm.Deprotection and DNA binding studies of DAPI and ethidium
derivatives
As with ©3, the bis-alloc DAPI derivative ©4 was readily
obtained in good yield by treatment of 4 with allyl chlor-
oformate and Et3N in DMSO. In contrast to DAPI, ©4 displays a
weak intrinsic uorescence, but experienced a comparatively
lower increase in emission when mixed with the h-A2$T2
hairpin oligonucleotide (Fig. 4). Steady state uorescence
titration of ©4 with this hairpin oligo revealed a Kd [©4] z 0.41
mM, which represents an affinity more than 40 times weaker
than that of DAPI (KD [4] # 10 nM).17 Likewise, as observed
previously with 3, inhibition of the DNA binding required the
protection of both amidinium groups, since the single pro-
tected DAPI still exhibited signicant DNA binding (Kd [m-©4]
z 49 nM, see the ESI†).
The Ru-catalyzed uncaging of ©4 was faster and more effi-
cient than that of ©3. Treatment of ©4 (25 mM) with thiophenol
(5 equiv.) and 10% of the ruthenium catalyst [Ru], in 100 mM
phosphate buffer pH 7.5 and 10% DMSO in the presence of ct-
DNA thus led to the desired parent compound 4 aer only 5 min
at rt (clean conversion by HPLC).
Finally, the catalytic uncaging strategy was also tested with
ethidium bromide (5), a classic intercalator that is widely used
for DNA and RNA staining.14 Commercially available ethidium
bromide (5) reacted efficiently with allyl chloroformate in DIEA/
DMF to yield the desired dialloc derivative ©5 as a bright yellowThis journal is © The Royal Society of Chemistry 2014solid (yield z 58%). Remarkably, in contrast to the parent
ethidium, the biscarbamate ©5 is highly uorescent in aqueous
solution in the absence of DNA, displaying a maximum emis-
sion wavelength at 510 nm (Fig. 5). While the addition of ct-DNA
to ethidium induces a signicant increase in its uorescence
emission at 595 nm, addition of ct-DNA to the bis-caged
ethidium ©5 leads to a decrease in its emission.18 As in the case
of the minor groove binders discussed previously, the caged
derivative displayed weaker DNA binding than the parentChem. Sci., 2014, 5, 1901–1907 | 1903
































































































View Article Onlineethidium: a nearly 20-fold decrease in affinity for h-AGA (see
the ESI†).
With regard to the catalytic uncaging, treatment of ©5
(50 mM) with thiophenol (5 equiv.) and 10% of [Ru] in phos-
phate buffer 100 mM pH 7.5 and 10% DMSO at rt in the pres-
ence of ct-DNA led to the expected uncaged products, although
the reaction is slower than in the case of ©4. HPLC of the
reaction mixture aer 20 min showed the formation of mono-
uncaged derivatives, however, aer 1 h most of the starting
material had been transformed into the desired fully depro-
tected product (5). Interestingly, since the absorption of the
protected derivative (©5) is different to that of the parent
ethidium, the reaction progress can be monitored by observing
changes in the solution color (inset in Fig. 6). Competitive
titrations with 5 showed that the monoprotected ethidium
derivatives also bind DNA, although with weaker affinity than
the parent ethidium (see the ESI†).Fig. 7 Ru-catalyzed deprotection of 2.5 mM©4 in CEF cells: (a)©4, 30
min at 37 C, blue channel; (b) ©4, 30 min at 37 C, brightfield; (c) ©4
treated with 2.5 mM [Ru] and 100 mM PhSH, 8 min, blue channel; (d)
©4 treatedwith 2.5 mM [Ru] and 100 mMPhSH, 8min, brightfield; (e)©4
treated 20 min with 2.5 mM [Ru] and 100 mM PhSH, 20 min, blue
channel; (f) ©4 treated 20 min with 2.5 mM [Ru] and 100 mM PhSH,
20 min, brightfield. (g) control with 2.5 mM 4 after 30 min at 37 C, blue
channel; (h) control with 15 mM 4 after 30 min, 37 C, blue channel.
Blue channel fluorescence microscopy settings: excitation filter 360–
370 nm, emission filter 420 nm and dichromatic mirror 400 nm.Uncaging experiments in living cells
The above results validate the attachment of alloc appendages
as an efficient strategy to considerably inhibit the DNA binding
of three different types of small DNA-binding agents, and
conrm the viability of metal-catalyzed removal of the caging
group under aqueous (and hypothetically biocompatible)
conditions. We therefore explored the possibility of performing
the catalytic de-allylation process to induce DNA binding in
cellular settings. We focused our efforts on the study of DAPI
and ethidium derivatives, because their cellular distribution
might be easily monitored by uorescence microscopy, thanks
to the intrinsic uorescence of the protected dyes and the
characteristic emission pattern of the parent dyes when bound
to the DNA (Fig. 4 and 5). Chicken embryo broblast (CEF) cells
were thus incubated with ©4 (2.5 mM) in serum-free medium for
30 min at 37 C. The medium was then removed and the wells
were rinsed twice with PBS to remove excess of©4. Fluorescence
microscopy (excitation lter 360–370 nm/emission lter
420 nm) showed blue staining of the whole cell, indicating that
the alloc-protected DAPI (©4) is evenly distributed in the cellsFig. 6 HPLC trace of the deprotection reaction of ©5. (a) ©5 in buffer
(50 mM); (b) ©5 + PhSH (250 mM) + ct-DNA (0.1 mg ml1); (c) ©5 +
PhSH + ct-DNA + Ru (10%) t ¼ 0; (d) ©5 + PhSH + ct-DNA + Ru t ¼
20 min; (e) ©5 + PhSH + ct-DNA + Ru t ¼ 1 h. Inset: picture (left to
right) of the aliquots a, b, c and e.
1904 | Chem. Sci., 2014, 5, 1901–1907(Fig. 7a). Aer washing twice with PBS, cells were resuspended
in media and treated with the ruthenium catalyst [Ru] dissolved
in DMSO (2.5 mM) and PhSH (100 mM) at 37 C, and observed
under the microscope at increasing incubation times (8 and
20 minutes). Aer 8 min (Fig. 7c), there is a relatively more
intense nuclear emission, but also blue staining of the cyto-
plasm, but aer 20 min the cells show the typical nuclear
staining of DAPI (Fig. 7e). The redistribution of the stain is
consistent with the expected deprotection reaction and the
liberation of 4. Interestingly, a control experiment in which cells
were incubated with 2.5 mM of DAPI resulted in very weak
emission from the cells (Fig. 7g), and the use of higher
concentrations of DAPI (up to 15 mM) was required to see a clear
staining (Fig. 7h). This enhanced staining efficiency resulting
from the uncaging of ©4, in comparison with that directly
obtained with DAPI (Fig. 7e and g), suggests that the dialloc-
derivative ©4 is internalized very efficiently and converted into
DAPI inside the cells, otherwise the staining intensity should
have been similar in both cases. Moreover, control experimentsThis journal is © The Royal Society of Chemistry 2014
Fig. 9 Ru-catalyzed deprotection of 10 mM ©5 in CEF cells. Left
column: ©5, 30 min at 37 C; (a) green channel; (b) brightfield; (c) red
channel. Right column: ©5 incubated with 20 mM [Ru] and 100 mM
PhSH, 20 min; (d) green channel; (e) brightfield; (f) red channel.
Fluorescence microscopy settings for green channel: filter 530–
550 nm, emission filter 590 nm and dichromatic mirror 570 nm; and
for red channel: filter 530–550 nm, emission filter 590 nm and
dichromatic mirror 570 nm.
































































































View Article Onlinedemonstrated that, before the addition of the ruthenium cata-
lyst, the medium shows almost no uorescence, suggesting that
©4 does not leak out of the cell signicantly (see the ESI†).
While further studies are needed, these results provide support
for an intracellular uncaging reaction.
In consonance with previous ndings by Meggers et al.,8 we
found that both the metal catalyst and the thiophenol additive
are required to obtain an efficient cellular uncaging (see the
ESI†). Importantly, cytotoxicity experiments using trypan blue,19
revealed that cells treated with 20 mM of [Ru] and 100 mM
PhSH display a fairly similar phenotypic viability to untreated
cultures (see the ESI†). Moreover, comparative staining with
propidium iodide (20 mM) showed that treatment of CEF cells
with the standard reaction cocktail does not apparently disrupt
the integrity of cell membranes (see the ESI†). As expected, the
uncaging process could be achieved in other cell types, such as
Vero cells from African green monkey kidney. Consistent with
the previous results with CEF cells, incubation of Vero cells with
protected DAPI (©4) leads to a more or less homogeneous
staining, with the dye evenly distributed between the cytoplasm
and the cell nuclei (Fig. 8a). Addition of the reagents (2.5 mM
[Ru] and 100 mM PhSH) led to a clear redistribution of the
emission into the cell nuclei (Fig. 8c), as expected for release of
the uncaged DAPI and its sticking to nuclear DNA.
With regard to the uncaging of ethidium, the distinctive
emission pattern of the protected and unprotected derivatives
allowed a detailed monitoring of the uncaging process. ©5 thus
gives a clear green staining of the cells (excitation lter 460–
490 nm/emission lter 520 nm), with a preferential accumula-
tion of the caged dye in cytoplasmatic structures (Fig. 9a). As
expected from the uorescence spectrum (Fig. 5), no emission
was observed in the red channel (excitation lter 530–550 nm/
emission lter 590 nm). Treatment of the cells with [Ru] (20
mM) and PhSH (100 mM) for 20 min led to the characteristic
staining of ethidium bromide in the red channel, with the
emission mainly concentrated in the nuclei and nucleoli
(Fig. 9f), while almost no signal was observed in the green
channel (Fig. 9d), suggesting that the uncaging had been very
efficient.Fig. 8 Ru-catalyzed deprotection of 2.5 mM of ©4 in Vero cells. Top
row: ©4, 30 min at 37 C (a) blue channel; (b) brightfield. Bottom row:
©4 with 2.5 mM [Ru] and 100 mM PhSH, 20 min; (c) blue channel; (d)
brightfield.
This journal is © The Royal Society of Chemistry 2014Biological activity
The above results demonstrate that caging key functional
groups of DNA binding agents, even with simple alloc moieties,
results in a signicant decrease in their DNA affinity. A potential
biomedical application of this chemistry required the demon-
stration that such a decrease in DNA binding is also associated
with a decreased biological effect. We therefore checked the
activity of the protected (©3) and unprotected bis-benzamidines
(3) against cancer cell lines. Interestingly, in the cisplatin-
resistant A2780 cell line (human ovarian carcinoma), the
inhibitory effect of the caged derivative was more than ten times
lower than that of the parent aza pentamidine (IC50 [©3] z
5.0 mM, IC50 [3] z 0.4 mM), which in turn had a stronger
inhibitory effect than cisplatin (IC50[cisplatin] z 7.4 mM).
Similar effects of the alloc caging were also observed with the
related A2780 cDDP cell line (IC50 [©3]z 5.1 mM, IC50 [3]z 0.9,
IC50[cisplatin] z 0.8). The ruthenium catalyst had negligible
inhibitory effect by itself with an IC50 $ 45 mM.20 These results
open the door to future pro-drug strategies that rely on the
combination of caged precursors and an appropriate metal
complex for controlled catalytic uncaging.Conclusions
In conclusion, we have demonstrated that installing simple
allylcarbamate groups in the key positions of several DNA
binders not only decreases their interaction with DNA, but also
modulates their spectroscopic properties and cellular location.Chem. Sci., 2014, 5, 1901–1907 | 1905
































































































View Article OnlineIn particular, we have demonstrated that the bis alloc-protected
derivatives of DAPI or ethidium bromide are weaker DNA
binders than the parent compounds, which can be efficiently
regenerated in aqueous buffers, and even in cellular environ-
ments, by reaction with a ruthenium catalytic system. Our
results set the stage for future developments on metal-catalyzed
activation of DNA-binding compounds in biological media.Acknowledgements
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